| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
IC50: 1.5 nM; Ki: 11.9 nM (BTK)[1]
|
|---|---|
| References |
|
| Additional Infomation |
1-(4-(((6-Amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)-4-fluoropiperidin-1-yl)prop-2-en-1-one is a potent, orally active, ATP-competitive, highly selective irreversible BTK inhibitor with an IC50 of 1.5 nM and a Ki of 11.9 nM. TL-895 is being investigated in multiple clinical trials to evaluate its safety and efficacy in various diseases: NCT04419623 (completed, COVID-19 cancer patients), NCT02825836 (ongoing, not recruiting, B-cell malignancies, including chronic lymphocytic leukemia), NCT05280509 (recruiting, in combination with ruxolitinib for myelofibrosis), NCT04655118 (recruiting, myelofibrosis), NCT04669067 (ongoing, not recruiting, acute myeloid leukemia in combination with KRT-232), NCT04640532 (recruiting, relapsed/refractory myelofibrosis and myelofibrosis intolerant to JAK inhibitors in combination with KRT-232), and NCT04878003 (recruiting, myelofibrosis not previously treated with Janus kinase inhibitors). TL-895, a BTK inhibitor, is a highly bioavailable, selective Bruton's tyrosine kinase (BTK) inhibitor with potential antitumor activity. After oral administration, TL-895 targets and covalently binds to BTK, thereby inhibiting its activity. This leads to suppression of B-cell receptor (BCR) signaling and inhibits the proliferation of B-cell malignant tumor cells. BTK is a cytoplasmic tyrosine kinase belonging to the Tec kinase family, playing a crucial role in the development, activation, signal transduction, proliferation, and survival of B lymphocytes.
Mechanism of Action TL-895 inhibits Bruton's tyrosine kinase, an enzyme associated with cancer growth. |
| Molecular Formula |
C25H26FN5O2
|
|---|---|
| Molecular Weight |
447.504648685455
|
| Exact Mass |
447.207
|
| CAS # |
1415823-49-2
|
| PubChem CID |
86721856
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
33
|
| Complexity |
643
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1(CNC2C(=C(N)N=CN=2)C2C=CC(=CC=2)OC2C=CC=CC=2)CCN(C(C=C)=O)CC1
|
| InChi Key |
OXOXFDSEGFLWLU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H26FN5O2/c1-2-21(32)31-14-12-25(26,13-15-31)16-28-24-22(23(27)29-17-30-24)18-8-10-20(11-9-18)33-19-6-4-3-5-7-19/h2-11,17H,1,12-16H2,(H3,27,28,29,30)
|
| Chemical Name |
1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]-4-fluoropiperidin-1-yl]prop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (558.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2346 mL | 11.1732 mL | 22.3464 mL | |
| 5 mM | 0.4469 mL | 2.2346 mL | 4.4693 mL | |
| 10 mM | 0.2235 mL | 1.1173 mL | 2.2346 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT04655118
Conditions:Myelofibrosis|Indolent Systemic MastocytosisLink: https://clinicaltrials.gov/ct2/show/NCT02825836
Conditions:Relapsed/Refractory B Cell Malignancies|Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Treatment-Naive B Cell MalignanciesLink: https://clinicaltrials.gov/ct2/show/NCT05280509
Conditions:Myelofibrosis|Primary Myelofibrosis|Post-PV MF|Post-ET Myelofibrosis
Title:TL-895 and KRT-232 Study in Acute Myeloid Leukemia
Status:Unknown status
updateDate:2023-02-17
Ctid:NCT04669067
Link: https://clinicaltrials.gov/ct2/show/NCT04669067
Conditions:Acute Myeloid LeukemiaLink: https://clinicaltrials.gov/ct2/show/NCT04878003
Conditions:Primary Myelofibrosis (PMF)|Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)|Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)Link: https://clinicaltrials.gov/ct2/show/NCT04640532
Conditions:Myelofibrosis|Post-PV MF|Post-ET Myelofibrosis|Primary MyelofibrosisLink: https://clinicaltrials.gov/ct2/show/NCT04419623
Conditions:COVID-19|Sars-CoV2|Cancer|Solid Tumor|Carcinoma|Blood CancerLink: https://clinicaltrials.gov/ct2/show/NCT03297983
Conditions:HealthyLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002259-39
Condition:Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in patients with cancerLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000286-23
Condition:B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
